Un épisode à ne pas manquer pour mieux comprendre le cerveau - Offert chaque jour par kodens.fr
Today · 4 min
SW
Short Wave
Science-backed guidance for healthy screen time
We’re all aware – and wary – of doomscrolling. Lots of screen time can be bad for us. But what if that’s not always the case? We spoke with the author of a study that found a positive relationship between screen time and brain development in young people. This episode, we sort through what to actually worry about when it comes to screen time – and what guidelines already exist that can empower you and the kids in your life.
Interested in learning more about how screen time affects your brain? Email us your question at shortwave@npr.org.
Support public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org.
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy
Today · 12 min
TP
The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
EASD 2026 Debrief: Type 2 Diabetes Care Moves Earlier & Foundayo Meets a Heart-Safety Bar
The Pharma Closeout's EASD 2026 Debrief covers the readouts from the European Association for the Study of Diabetes meeting in Milan that matter for drug, device and payer strategy. The new ADA/EASD consensus reportmoves GLP-1 and SGLT2 drugs earlier in type 2 diabetes care, potentially from diagnosis, and prefers weight-lowering drugs for people with overweight orobesity. Lilly's ACHIEVE-4 put its oral GLP-1 pill Foundayo against insulin and met a heart-safety bar. Real-world data arrived from Novo on stepping up semaglutide versus switching, from Abbott on continuous glucose monitors, and from a Nordic study on semaglutide and pancreatic cancer. Plus the journal papers on retatrutide, survodutide and petrelintide, type 1 diabetes screening in children across Europe, and what to watch: Lilly and Novo results and ObesityWeek.
0:00 Cold open and introduction
1:12 Story of the Congress: type 2 diabetes care moves earlier
2:54 Lilly's Foundayo vs insulin: ACHIEVE-4 heart safety
4:57 Real-world evidence: Novo's switch data, Abbott's glucose monitors, semaglutide and pancreatic cancer
9:20 Obesity: the retatrutide, survodutide and petrelintide papers
13:59 Type 1 diabetes: screening children across Europe
15:51 What to watch: Lilly and Novo results, ObesityWeek
Alex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at https://thepharmacloseout.com.
